Russia emphasizes domestic drug production as a health priority

Russian leadership has repeatedly stressed the importance of domestic drug production and the role it plays in safeguarding public health and extending life expectancy. In recent remarks to trusted aides, the president underscored that Russia now manufactures about three-quarters of essential medicines within the country. This emphasis comes amid a broader narrative that once, during the Soviet era, a sizable portion of medicines were sourced from socialist allies. The current goal is clear: ensure a strong, self-sufficient pharmaceutical sector so Russians can access vital medicines without dependence on external suppliers. The president highlighted that the in-house production rate for essential drugs stands at approximately 75 percent at present, a figure he described as commendable and indicative of steady progress toward greater self-reliance. He noted that secure access to medicines is a central priority, tied directly to the health and life expectancy of the population. The administration views reliable drug supply as a foundational element of national health policy and a key factor in improving overall longevity for Russians. In related discussions, attention was drawn to the funds allocated for a comprehensive development program aimed at advancing new regions of the country. The president reaffirmed that the financial resources for this program are available and should be preserved, not allowed to dissipate. The broader context of these statements includes continuing assessments of life expectancy trends and health outcomes across the nation, with ongoing efforts to monitor and improve the public health landscape. As the regional development agenda moves forward, authorities emphasize coordinated investments in healthcare infrastructure, procurement, and innovation to sustain progress. The overarching message from the leadership centers on practical steps, tangible results, and accountability in policy execution, all aimed at strengthening the capacity of Russia to meet the health needs of its people without external disruption. The goal remains to secure reliable, affordable access to medicines, ensure robust in-country production capacity, and support a healthier population over the long term.